Fairvalue-Calculator Fairvalue-Calculator
EN DE

Radiopharm Theranostics Limited (RAD) Fair Value & Analysis

Healthcare · AU · Market cap A$47.3M

PriceA$0.0190
Fair ValueA$0.0173
Upside-9.0%
Quality92/100
Evidence: Low Range A$0.0173 – A$0.0192

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Radiopharm Theranostics Limited (RAD) currently trades at A$0.0190, while our model-based Fair Value estimate is A$0.0173 — implying the stock looks roughly 9.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The compa…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Radiopharm Theranostics Limited (RAD) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.0173 versus a price of A$0.0190 — about −9% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RAD?
Our 21-model fair value for Radiopharm Theranostics Limited is A$0.0173 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.0190.
What is the quality score of RAD?
Radiopharm Theranostics Limited has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.